For the period 2010-2015, over 4,000 clinical trials commenced in South Korea and while another 2,000 were started in Taiwan. In contrast, fewer than 1,000 were started in Thailand. However, that situation may now be changing. Clinical trials contributed $270 million to Thailand’s GDP, which represented 0.05% of its GDP for 2015. Trials conducted in 2015 are expected to generate a 4.2 percent rate of return in net present values. The long-term economic return of medicines produced from those trials is expected to be $13.4 million. (Source: Clinical Leader)

For full text of the news  click here.

2017-03-10T09:46:10+00:00